Companies like ours are always raising capital to fund expansion and growth. So, the answer is yes, there are opportunities for private investment, prior to going public. You can get in touch with us through our website, or email our CFO directly [email protected]
On that same note, in 2017, it was reported that Aphria had invested in $11.5M in Scientus Pharma. I mention that so potential investors have an increased level of confidence. Let’s quickly also look at two recent significant news releases. Can you advise on each one of these please?
Scientus Pharma Receives U.S. Patent for Decarboxylated Cannabis Resins Method.
Scientus Pharma Provides Update on Buccal Cannabis Development Program
We are a product innovation company so those are two of the advances that we are most proud of. Our first patent for our extraction and decarboxylation platform is central to our business model. It is the first step only. When companies file patent applications, the strategy is to establish a foundation, and then “broaden the moat” from that position. Our first patent was granted by the US patent office. It is followed by filings in other jurisdictions globally, and followed by related technologies that strengthen our foundation. For us, that is composition of matter, design and apparatus and formulation patents that build on the first methods patent.
The second announcement is also related to product innovation. And that is our buccal spray product. This is an elegant drug delivery technology that delivers active pharmaceutical ingredients directly into the bloodstream through the membranes in you mouth and back of the throat. You will hear much more on this in the next 12-24 months, so stay tuned.
117